1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


Delayed Quote. Delayed Nasdaq Copenhagen - 05/20 10:59:42 am
761.3 DKK   +4.16%
05/20European ADRs Move Sharply Higher in Friday Trading
05/20NOVO NORDISK : Berenberg remains Neutral
05/16European ADRs Move Higher in Monday Trading
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

2seventy bio, Inc. Announces Expanded Collaboration Agreement with Novo Nordisk to Continue Development of in Vivo Gene Editing Approach

01/06/2022 | 07:00am EDT

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for hemophilia A patients with the goal of offering a sustained therapeutic effect. The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in 2019, focused on identifying a development gene therapy candidate for people with hemophilia A. The collaboration utilizes 2seventy bio’s megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit, or insert genetic components. Hemophilia A is a genetic bleeding disorder resulting from defective Factor VIII. Under the terms of the agreement, Novo Nordisk will obtain the option to exclusively license 2seventy bio’s in vivo mRNA platform and gene editing technology for use in the treatment of patients with hemophilia A. 2seventy bio will receive an upfront payment of $5 million and is eligible for near-term milestone and option exercise payments of up to $35 million, in addition to development, regulatory, and commercial milestones, as well as a royalty on net sales. Novo Nordisk will be responsible for funding all research and development activities. Related to this collaboration, 2seventy bio has also entered into an agreement with Genevant Sciences for access to Genevant’s LNP technology platform for use in 2seventy bio’s collaboration with Novo Nordisk for the treatment of patients with hemophilia A. 2seventy bio plans to use the Genevant LNP platform for efficient delivery of megaTAL mRNA to hepatocyte cells within the liver. Under the terms of the agreement between 2seventy bio and Genevant, 2seventy bio obtained rights to license Genevant’s LNP technology for use with megaTAL mRNA products in the treatment of patients with hemophilia A. Genevant is eligible for upfront and near-term option exercise payments totaling $10 million, as well as development and commercialization milestones, and royalties in the mid-single digits on future product sales.

© S&P Capital IQ 2022
All news about NOVO NORDISK A/S
05/20European ADRs Move Sharply Higher in Friday Trading
05/20NOVO NORDISK : Berenberg remains Neutral
05/16European ADRs Move Higher in Monday Trading
05/16NOVO NORDISK A/S : Share repurchase programme
05/16NOVO NORDISK A/S : Share repurchase programme
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
05/12NOVO NORDISK : Barclays gives a Buy rating
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2022 166 B 23 554 M 23 554 M
Net income 2022 52 875 M 7 494 M 7 494 M
Net cash 2022 4 087 M 579 M 579 M
P/E ratio 2022 32,4x
Yield 2022 1,51%
Capitalization 1 729 B 245 B 245 B
EV / Sales 2022 10,4x
EV / Sales 2023 9,16x
Nbr of Employees 49 295
Free-Float 69,6%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 761,30 DKK
Average target price 791,88 DKK
Spread / Average Target 4,02%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.58%245 099
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707